{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:15:13Z","timestamp":1790234113959,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.01.030","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T20:47:28Z","timestamp":1518036448000},"page":"S95-S107","source":"Crossref","is-referenced-by-count":118,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)"],"prefix":"10.1016","volume":"24","author":[{"given":"G.","family":"Redelman-Sidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.01.030_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.030_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A\u00a0new member of the immunoglobulin superfamily\u2014CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2018.01.030_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib4","first-page":"322","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.cmi.2018.01.030_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cmi.2018.01.030_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib7","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A\u00a0clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2018.01.030_bib13","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte\u2013associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib14","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000165","article-title":"Ipilimumab-induced colitis in patients with metastatic melanoma","volume":"25","author":"De Felice","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cmi.2018.01.030_bib17","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.cmi.2018.01.030_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1040218","article-title":"Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control","volume":"4","author":"Arriola","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cmi.2018.01.030_bib20","first-page":"212","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.cmi.2018.01.030_bib21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib22","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2018.01.030_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2018.01.030_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cmi.2018.01.030_bib25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib27","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib28","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti\u2013programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.01.030_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2018.01.030_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.01.030_bib32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non\u2013small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.01.030_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti\u2013PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cmi.2018.01.030_bib34","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib35","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib36","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti\u2013programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.030_bib39","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti\u2013PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.289","article-title":"Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab","volume":"6","author":"Uchida","year":"2018","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.cmi.2018.01.030_bib41","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(17)30852-5","article-title":"Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis","volume":"18","author":"Daver","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib42","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/cc13176","article-title":"Targeting the programmed cell death 1:programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis","volume":"18","author":"Chang","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2018.01.030_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(13)70111-6","article-title":"Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Rigby","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2018.01.030_bib45","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","article-title":"Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts","volume":"139","author":"Gordon","year":"2003","journal-title":"Arch Dermatol"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.cmi.2018.01.030_bib46","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.2310\/7750.2009.00032","article-title":"Update on alefacept safety","volume":"13","author":"Wexler","year":"2009","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.cmi.2018.01.030_bib47","first-page":"411","article-title":"The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis","volume":"3","author":"Jenneck","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cmi.2018.01.030_bib48","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2018.01.030_bib50","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib52","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"del Pilar Martin","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.cmi.2018.01.030_bib54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus\u2013induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2018.01.030_bib56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy\u2014revisited","volume":"203","author":"White","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib57","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1128\/JVI.72.12.9918-9923.1998","article-title":"Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection","volume":"72","author":"Monaco","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2018.01.030_bib58","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/514161","article-title":"Review: JC virus infection of lymphocytes\u2014revisited","volume":"176","author":"Gallia","year":"1997","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib59","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/NEN.0b013e318180e631","article-title":"Potential mechanisms of the human polyomavirus JC in neural oncogenesis","volume":"67","author":"Del Valle","year":"2008","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib62","first-page":"2004","article-title":"Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases","volume":"263","author":"Maas","year":"2016","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib63","first-page":"1920","article-title":"Progressive multifocal leukoencephalopathy and natalizumab","volume":"258","author":"Hellwig","year":"2011","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1468-1331.2011.03597.x","article-title":"Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis","volume":"19","author":"Sahraian","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?","volume":"67","author":"Warnke","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib68","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib70","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A\u00a0second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cmi.2018.01.030_bib72","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cmi.2018.01.030_bib73","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib74","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJMc1207116","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"367","author":"Cervera","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib75","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib76","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","article-title":"Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis","volume":"190","author":"Haanstra","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.01.030_bib77","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cmi.2018.01.030_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2018.01.030_bib80","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(14)70067-5","article-title":"Effects of fingolimod in relapsing-remitting multiple sclerosis","volume":"13","author":"Sorensen","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib81","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1\u2013phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cmi.2018.01.030_bib82","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1\u2013phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cmi.2018.01.030_bib83","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1074\/jbc.M610318200","article-title":"Immunosuppressive and anti\u2013angiogenic sphingosine 1\u2013phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor","volume":"282","author":"Oo","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cmi.2018.01.030_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ni1534","article-title":"The sphingosine 1\u2013phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics","volume":"9","author":"Ledgerwood","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cmi.2018.01.030_bib85","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200526218","article-title":"Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720","volume":"35","author":"Morris","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cmi.2018.01.030_bib86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i\u2013coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2018.01.030_bib87","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib88","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0091270004264165","article-title":"Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects","volume":"44","author":"Kovarik","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2018.01.030_bib89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.cmi.2018.01.030_bib90","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2009.08.043","article-title":"Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection","volume":"397","author":"Walsh","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.cmi.2018.01.030_bib91","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib92","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib93","doi-asserted-by":"crossref","first-page":"227","DOI":"10.33588\/rn.5504.2012164","article-title":"Infections and fingolimod","volume":"55","author":"Cervera","year":"2012","journal-title":"Rev Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib95","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib96","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1212\/WNL.0000000000001659","article-title":"Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis","volume":"84","author":"Pfender","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib97","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jiac.2016.07.011","article-title":"Herpes zoster laryngitis in a patient treated with fingolimod","volume":"22","author":"Hagiya","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2018.01.030_bib98","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/cid\/ciu058","article-title":"Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine","volume":"58","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.030_bib99","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cmi.2018.01.030_bib100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/14712598.2016.1134481","article-title":"The herpes zoster subunit vaccine","volume":"16","author":"Cunningham","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cmi.2018.01.030_bib101","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib102","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib104","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","article-title":"Disseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod","volume":"55","author":"Seto","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.msard.2016.06.007","article-title":"Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis","volume":"9","author":"Ward","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.cmi.2018.01.030_bib106","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1352458514555788","article-title":"Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient","volume":"21","author":"Artemiadis","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.cmi.2018.01.030_bib107","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/1352458516629560","article-title":"Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod","volume":"22","author":"Behle","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.cmi.2018.01.030_bib108","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","article-title":"Fingolimod-associated PML in a patient with prior immunosuppression","volume":"86","author":"Gyang","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.01.030_bib109","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","article-title":"Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"14","author":"Faulkner","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2018.01.030_bib110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib111","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib112","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.030_bib113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.01.030_bib114","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaneurol.2016.2588","article-title":"Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis","volume":"73","author":"Behrendt","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cmi.2018.01.030_bib115","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/TP.0000000000000694","article-title":"A\u00a0Banff component scoring\u2013based histologic assessment of bortezomib-based antibody-mediated rejection therapy","volume":"99","author":"Sadaka","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.01.030_bib116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.01.030_bib117","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2559.2009.03263.x","article-title":"Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment","volume":"54","author":"Wondergem","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.cmi.2018.01.030_bib118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","article-title":"Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma","volume":"8","author":"Kim","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.cmi.2018.01.030_bib119","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.01.030_bib120","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00520-014-2550-3","article-title":"Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital","volume":"23","author":"Teh","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2018.01.030_bib121","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cup.12338","article-title":"A\u00a0case of protothecosis in a patient with multiple myeloma","volume":"41","author":"Figueroa","year":"2014","journal-title":"J\u00a0Cutan Pathol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:52:13Z","timestamp":1751367133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18301484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":121,"alternative-id":["S1198743X18301484"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.01.030","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}